Supplementary Figure. Viral RNA Shedding Levels for Individual Subjects With Viral RNA Rebound Among Subjects in the EPIC-HR Trial Who Met the Definitions of Posttreatment Viral RNA Rebound on Day 10 (a) or 14 (B); Those Who Met the Definition of Viral RNA Rebound During the Treatment Period From Day 3 to Day 5* (C, D); Those in the EPIC-SR 2021/Pre-Omicron (E) and 2022/Omicron Enrollment Periods (F), Who Met the Definition of Day 10 or Day 14 Viral RNA Rebound

Details

• Alternative Title:
  Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022: Supplementary Figure. Viral RNA Shedding Levels for Individual Subjects With Viral RNA Rebound Among Subjects in the EPIC-HR Trial Who Met the Definitions of Posttreatment Viral RNA Rebound on Day 10 (a) or 14 (B); Those Who Met the Definition of Viral RNA Rebound During the Treatment Period From Day 3 to Day 5* (C, D); Those in the EPIC-SR 2021/Pre-Omicron (E) and 2022/Omicron Enrollment Periods (F), Who Met the Definition of Day 10 or Day 14 Viral RNA Rebound
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 51
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  72
• Issue:
  51
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:3acfaca33598d65d85b284c876218aae47bc6389aafd0a5626039c9a60b213f99c563c9c36ac6113dce8a285c17f7e354c7c50f37db629544d671ac54aeff402
• Download URL:
  https://stacks.cdc.gov/view/cdc/136167/cdc_136167_DS1.pdf
• File Type:
  [PDF - 1.13 MB ]